US-based biopharmaceutical services company Quintiles has intensified a 14-year commitment to the Chinese market by launching a local contract research organisation, Kun Tuo.
Quintiles already had a firm footing in China, operating out of offices in Beijing, Shanghai and Hong Kong. In early 2008, the company consolidated and expanded its Global Central Laboratories and Clinical Development Services units at a single facility in Beijing to accommodate a growing business in China.
Kun Tuo will reinforce this presence by servicing the “unique needs” of both the Chinese biopharmaceutical industry and locally active multinationals, its parent said. The focus will be on developing customised solutions to help these clients achieve successful registration of new medicines in China.
The new CRO will provide a full range of contract research services, including comprehensive clinical trial management, preparation of regulatory submissions, biostatistics and data management.
Kun Tuo will also tap Quintiles’ global resources and expertise to develop customised offerings in key therapeutic areas as well as for vaccines, late-phase studies, medical devices and diagnostics.
“Kun Tuo will leverage Quintiles’ quality and training systems to offer customised, high-quality solutions best suited for local Chinese biopharma as well as global biopharma local affiliates,” commented Ling Zhen, general manager, Quintiles China.He noted the company’s “aggressive” growth plan for China, which includes doubling Quintiles’ overall staffing during 2012. Quintiles China already has more than 300 staff covering all population centres and study sites in China.